722 related articles for article (PubMed ID: 19553925)
1. Nonalcoholic hepatic steatosis in Zucker diabetic rats: spontaneous evolution and effects of metformin and fenofibrate.
Forcheron F; Abdallah P; Basset A; del Carmine P; Haffar G; Beylot M
Obesity (Silver Spring); 2009 Jul; 17(7):1381-9. PubMed ID: 19553925
[TBL] [Abstract][Full Text] [Related]
2. Adiponectin receptors: expression in Zucker diabetic rats and effects of fenofibrate and metformin.
Metais C; Forcheron F; Abdallah P; Basset A; Del Carmine P; Bricca G; Beylot M
Metabolism; 2008 Jul; 57(7):946-53. PubMed ID: 18555836
[TBL] [Abstract][Full Text] [Related]
3. Discordance between intramuscular triglyceride and insulin sensitivity in skeletal muscle of Zucker diabetic rats after treatment with fenofibrate and rosiglitazone.
Nadeau KJ; Ehlers LB; Aguirre LE; Reusch JE; Draznin B
Diabetes Obes Metab; 2007 Sep; 9(5):714-23. PubMed ID: 17697064
[TBL] [Abstract][Full Text] [Related]
4. PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes.
Seo YS; Kim JH; Jo NY; Choi KM; Baik SH; Park JJ; Kim JS; Byun KS; Bak YT; Lee CH; Kim A; Yeon JE
J Gastroenterol Hepatol; 2008 Jan; 23(1):102-9. PubMed ID: 18171348
[TBL] [Abstract][Full Text] [Related]
5. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver.
Harano Y; Yasui K; Toyama T; Nakajima T; Mitsuyoshi H; Mimani M; Hirasawa T; Itoh Y; Okanoue T
Liver Int; 2006 Jun; 26(5):613-20. PubMed ID: 16762007
[TBL] [Abstract][Full Text] [Related]
6. Salacia oblonga root improves postprandial hyperlipidemia and hepatic steatosis in Zucker diabetic fatty rats: activation of PPAR-alpha.
Huang TH; Peng G; Li GQ; Yamahara J; Roufogalis BD; Li Y
Toxicol Appl Pharmacol; 2006 Feb; 210(3):225-35. PubMed ID: 15975614
[TBL] [Abstract][Full Text] [Related]
7. Fenofibrate prevents orotic acid--induced hepatic steatosis in rats.
Ferreira AV; Parreira GG; Porto LC; Mario EG; Delpuerto HL; Martins AS; Botion LM
Life Sci; 2008 Apr; 82(15-16):876-83. PubMed ID: 18374364
[TBL] [Abstract][Full Text] [Related]
8. PPAR-alpha agonist fenofibrate induces renal CYP enzymes and reduces blood pressure and glomerular hypertrophy in Zucker diabetic fatty rats.
Zhao X; Li LY
Am J Nephrol; 2008; 28(4):598-606. PubMed ID: 18277067
[TBL] [Abstract][Full Text] [Related]
9. Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555.
Upton R; Widdowson PS; Ishii S; Tanaka H; Williams G
Br J Pharmacol; 1998 Dec; 125(8):1708-14. PubMed ID: 9886762
[TBL] [Abstract][Full Text] [Related]
10. Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats.
Laurent D; Gounarides JS; Gao J; Boettcher BR
Diabetes Obes Metab; 2009 Jun; 11(6):632-6. PubMed ID: 19175377
[TBL] [Abstract][Full Text] [Related]
11. Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease.
Hong XZ; Li LD; Wu LM
Clin Exp Pharmacol Physiol; 2007; 34(1-2):27-35. PubMed ID: 17201732
[TBL] [Abstract][Full Text] [Related]
12. Pomegranate flower ameliorates fatty liver in an animal model of type 2 diabetes and obesity.
Xu KZ; Zhu C; Kim MS; Yamahara J; Li Y
J Ethnopharmacol; 2009 Jun; 123(2):280-7. PubMed ID: 19429373
[TBL] [Abstract][Full Text] [Related]
13. Fenofibrate prevents Rosiglitazone-induced body weight gain in ob/ob mice.
Carmona MC; Louche K; Nibbelink M; Prunet B; Bross A; Desbazeille M; Dacquet C; Renard P; Casteilla L; Pénicaud L
Int J Obes (Lond); 2005 Jul; 29(7):864-71. PubMed ID: 15917863
[TBL] [Abstract][Full Text] [Related]
14. Diabetic cardiomyopathy: effects of fenofibrate and metformin in an experimental model--the Zucker diabetic rat.
Forcheron F; Basset A; Abdallah P; Del Carmine P; Gadot N; Beylot M
Cardiovasc Diabetol; 2009 Mar; 8():16. PubMed ID: 19317897
[TBL] [Abstract][Full Text] [Related]
15. Effects of fenofibrate and insulin on the biosynthesis of unsaturated fatty acids in streptozotocin diabetic rats.
Montanaro MA; Bernasconi AM; González MS; Rimoldi OJ; Brenner RR
Prostaglandins Leukot Essent Fatty Acids; 2005 Nov; 73(5):369-78. PubMed ID: 16099631
[TBL] [Abstract][Full Text] [Related]
16. Lipase maturation factor 1: its expression in Zucker diabetic rats, and effects of metformin and fenofibrate.
Forcheron F; Basset A; Del Carmine P; Beylot M
Diabetes Metab; 2009 Dec; 35(6):452-7. PubMed ID: 19854668
[TBL] [Abstract][Full Text] [Related]
17. Phenotype-based treatment of dietary obesity: differential effects of fenofibrate in obesity-prone and obesity-resistant rats.
Ji H; Outterbridge LV; Friedman MI
Metabolism; 2005 Apr; 54(4):421-9. PubMed ID: 15798946
[TBL] [Abstract][Full Text] [Related]
18. Left-ventricular diastolic dysfunction may be prevented by chronic treatment with PPAR-alpha or -gamma agonists in a type 2 diabetic animal model.
Kim SK; Zhao ZS; Lee YJ; Lee KE; Kang SM; Choi D; Lim SK; Chung N; Lee HC; Cha BS
Diabetes Metab Res Rev; 2003; 19(6):487-93. PubMed ID: 14648808
[TBL] [Abstract][Full Text] [Related]
19. Current biochemical studies of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis suggest a new therapeutic approach.
Hookman P; Barkin JS
Am J Gastroenterol; 2003 Sep; 98(9):2093-7. PubMed ID: 14499793
[TBL] [Abstract][Full Text] [Related]
20. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
Cong WN; Tao RY; Tian JY; Liu GT; Ye F
Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]